ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 6 for:    sentinel node radiotherapy netherlands
Previous Study | Return to List | Next Study

Mapping of Sentinel Lymph Node Drainage Using SPECT (SUSPECT) (SUSPECT) (SUSPECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02572661
Recruitment Status : Active, not recruiting
First Posted : October 9, 2015
Last Update Posted : March 13, 2018
Sponsor:
Information provided by (Responsible Party):
The Netherlands Cancer Institute

Brief Summary:
This study aims to explore the feasibility, safety and outcome of a non‐invasive sentinel node mapping (SNM) to individually tailor the elective nodal irradiation (ENI) to the ipsilateral neck only and to exclude the contralateral negative neck from the irradiation fields when there is no draining sentinel node. Subsequently the dose to the salivary glands, mucosal area and the swallowing and chewing muscles and structures involved in voicing and articulation will significantly be reduced

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Radiation: radiation in Squamous Head and Neck Cancer Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 61 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Mapping of Sentinel Lymph Node Drainage Using SPECT to Tailor Highly‐Selective Elective Nodal Irradiation in Node‐Negative Neck of Patients With Head and Neck Cancer (SUSPECT)
Actual Study Start Date : July 23, 2015
Actual Primary Completion Date : November 9, 2017
Estimated Study Completion Date : November 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Squamous Head and Neck Cancer
radiation
Radiation: radiation in Squamous Head and Neck Cancer



Primary Outcome Measures :
  1. Feasibility and safety of single side radiation therapy measured by physical examination and toxicity measurement by CTCAE 4.03 at 12 weeks [ Time Frame: 12 weeks ]
    mapping of sentinel lymph node drainage to indentify groups at low risk of the probability of contra regionale failure is to be estimated to be 2% at 2 years. A recurrrence rate of >15% will be assumed unacceptable



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosed patients with histopathologic proven primary HNSCC (T1 ‐3 N0 ‐1) located in the oral cavity, oropharynx, larynx (except T1 glottic ), and hypopharynx, not crossing the midline and planned for treatment with (chemo)radiotherapy in curative setting
  • No chemotherapy or surgery prior to inclusion
  • No distant metastatic spread at the time of inclusion
  • Age ≥ 18 years
  • WHO performance status 0 or 1
  • Signed written informed consent

Exclusion Criteria:

  • Patients with previously radiation treatment in the head and neck region, for any reason
  • Patients with previous neck dissection
  • Patients with recurrent or second primary tumor in the head and neck region
  • Patients with head and neck malignancies arising from skin, lip, nose, sinuses, nasopharynx, salivary glands, thyroid gland or esophagus
  • Previous history of cancer in the last five years (excluding basal cell carcinoma of the skin and in situ SCC of the cervix)
  • Pregnancy or no active contraception for pre-menopausal women
  • Known hypersensitivity to iodine or nanocolloid injection
  • Having any condition (physical, mental, sociological) that interferes with the informed consent procedure and follow up schedules

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02572661


Locations
Netherlands
the Netherlands Cancer Instiute
Amsterdam, Netherlands, 1066 CX
Sponsors and Collaborators
The Netherlands Cancer Institute
Investigators
Principal Investigator: Abrahim Al-Mamgani, MD, PhD The Netherlands Cancer Institute

Responsible Party: The Netherlands Cancer Institute
ClinicalTrials.gov Identifier: NCT02572661     History of Changes
Other Study ID Numbers: N14SUS
N14SUS ( Registry Identifier: PTC )
NL51706.031.14 ( Registry Identifier: CCMO )
First Posted: October 9, 2015    Key Record Dates
Last Update Posted: March 13, 2018
Last Verified: March 2018

Keywords provided by The Netherlands Cancer Institute:
Radiotherapy, Sentinel Node Mapping, Spect

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms